Search...
GENSCRIPT BIO: CARVYKTI® generated net trade sales of approximately USD 524 million for the quarter ended September 30, 2025
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, GENSCRIPT BIO announced that, based on the collaboration and licensing agreement signed with Janssen Biotech, Inc. on December 21, 2017, CARVYKTI® is expected to generate net trade sales of approximately USD 524 million for the quarter ending September 30, 2025
According to the news from Zhitong Finance APP, GENSCRIPT BIO (01548) announced that, based on the collaboration and licensing agreement signed with Janssen Biotech, Inc. on December 21, 2017, CARVYKTI® is expected to generate approximately USD 524 million in net trade sales for the quarter ending September 30, 2025
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments